Your browser doesn't support javascript.
loading
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Rajan, Arun; Kelly, Ronan J; Trepel, Jane B; Kim, Yeong Sang; Alarcon, Sylvia V; Kummar, Shivaani; Gutierrez, Martin; Crandon, Sonja; Zein, Wadih M; Jain, Lokesh; Mannargudi, Baskar; Figg, William D; Houk, Brett E; Shnaidman, Michael; Brega, Nicoletta; Giaccone, Giuseppe.
Affiliation
  • Rajan A; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Clin Cancer Res ; 17(21): 6831-9, 2011 Nov 01.
Article in En | MEDLINE | ID: mdl-21908572
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzamides / HSP90 Heat-Shock Proteins / Indazoles / Lymphoma / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzamides / HSP90 Heat-Shock Proteins / Indazoles / Lymphoma / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: Country of publication: